Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Archives of Internal Medicine

• Publication date

  1994-07-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHINTE.1994.00420140015002PMID 8031204
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.

  1994cited by this paper
• The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia.

  1993cited by this paper
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

  1993cited by this paper
• Triglyceride, high density lipoprotein, and coronary heart disease.

  1993cited by this paper
• The effect of aspirin on niacin-induced cutaneous reactions.

  1992cited by this paper
• Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.

  1991cited by this paper
• Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.

  1991cited by this paper
• Lipoproteins and atherogenesis. Current concepts.

  1990cited by this paper
• An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence.

  1990cited by this paper
• Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.

  1990cited by this paper
• High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

  1989cited by this paper
• Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio.

  1989cited by this paper
• [Drug treatment of hyperlipoproteinemia].

  1987cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.

  1987cited by this paper
• Lp(a) lipoprotein as a risk factor for myocardial infarction.

  1986cited by this paper
• Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin.

  1985cited by this paper
• Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.

  1985cited by this paper
• Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease.

  1983cited by this paper
• Serum lipids in angiographically assessed coronary atherosclerosis.

  1978cited by this paper
• Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice.

  1961cited by this paper
• Influence of nicotinic acid on serum cholesterol in man.

  1955cited by this paper

• The role of pharmacological interventions in managing hyperlipidemia: A closer look at different drugs

  2024cites this paper
• Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance

  2022cites this paper
• Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

  2019cites this paper
• Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue

  2018cites this paper
• Epidemiology and management of hyperlipidemia.

  2017cites this paper
• Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease

  2016cites this paper
• Niacin: from mechanisms of action to therapeutic uses.

  2010cites this paper
• Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia

  2010cites this paper
• Emerging drugs for hyperlipidemia

  2010cites this paper
• The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review.

  2010cites this paper
• Therapeutic options for premature coronary artery disease

  2008cites this paper
• HDL cholesterol: physiology, pathophysiology, and management.

  2007cites this paper
• Assessment and management of lipid disorders in men.

  2006cites this paper
• Management of dyslipidemias in the age of statins.

  2003cites this paper
• Pharmaceutical initiatives to combat atherosclerosis--what to do with the good, the bad, and the ugly lipoproteins.

  2002cites this paper
• Experience with Crystalline Niacin as the Preferred Drug for Dyslipidemia in a Specialty Clinic

  1997cites this paper
• Comparative study on the in vivo and in vitro antilipolytic effects of etofibrate, nicotinic acid and clofibrate in the rat.

  1996cites this paper
• Xanthelasmas and xanthomas — cutaneous clues to systemic lipid disorders

  1995cites this paper
• LOVASTATIN OR NIACIN FOR HYPERCHOLESTEROLEMIA

  1994cites this paper